1. Jiang, Peng, Gu, Shengqing, Pan, Deng, Wucherpfennig, Kai W, Liu, X Shirley. 2018. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. In Nature medicine, 24, 1550-1558. doi:10.1038/s41591-018-0136-1. https://pubmed.ncbi.nlm.nih.gov/30127393/
2. Jiang, Liwei, Wang, Yi-Jun, Zhao, Jing, Dhe-Paganon, Sirano, Abdi, Reza. . Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy. In Cell, 183, 1219-1233.e18. doi:10.1016/j.cell.2020.10.045. https://pubmed.ncbi.nlm.nih.gov/33242418/
3. Ibáñez-Molero, Sofía, van Vliet, Alex, Pozniak, Joanna, Wessels, Lodewyk, Peeper, Daniel S. 2022. SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response. In Oncoimmunology, 11, 2139074. doi:10.1080/2162402X.2022.2139074. https://pubmed.ncbi.nlm.nih.gov/36465485/
4. van der Burgh, Robert, Meeldijk, Jan, Jongeneel, Lieneke, van Gijn, Mariëlle, Boes, Marianne. . Reduced serpinB9-mediated caspase-1 inhibition can contribute to autoinflammatory disease. In Oncotarget, 7, 19265-71. doi:10.18632/oncotarget.8086. https://pubmed.ncbi.nlm.nih.gov/26992230/
5. Harada, Mamoru, Kotani, Hitoshi, Iida, Yuichi, Yoshikawa, Kazuhiro, Uemura, Hirotsugu. 2024. Hypoxia-related carbonic anhydrase 9 induces serpinB9 expression in cancer cells and apoptosis in T cells via acidosis. In Cancer science, 115, 1405-1416. doi:10.1111/cas.16133. https://pubmed.ncbi.nlm.nih.gov/38413363/
6. Ekert, P G, Silke, J, Vaux, D L. . Caspase inhibitors. In Cell death and differentiation, 6, 1081-6. doi:. https://pubmed.ncbi.nlm.nih.gov/10578177/